Ocular Therapeutix Past Earnings Performance
Past criteria checks 0/6
Ocular Therapeutix has been growing earnings at an average annual rate of 0.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 39.4% per year.
Key information
0.6%
Earnings growth rate
18.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 39.4% |
Return on equity | -36.6% |
Net Margin | -226.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event
Aug 15Revenue & Expenses Breakdown
How Ocular Therapeutix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 61 | -138 | 89 | 0 |
31 Mar 24 | 60 | -115 | 79 | 0 |
31 Dec 23 | 58 | -81 | 74 | 0 |
30 Sep 23 | 58 | -67 | 76 | 0 |
30 Jun 23 | 55 | -91 | 77 | 0 |
31 Mar 23 | 52 | -89 | 75 | 0 |
31 Dec 22 | 51 | -71 | 72 | 0 |
30 Sep 22 | 50 | -59 | 70 | 0 |
30 Jun 22 | 50 | -33 | 69 | 0 |
31 Mar 22 | 49 | -22 | 68 | 0 |
31 Dec 21 | 44 | -7 | 67 | 0 |
30 Sep 21 | 39 | -88 | 64 | 0 |
30 Jun 21 | 32 | -103 | 59 | 0 |
31 Mar 21 | 22 | -131 | 53 | 0 |
31 Dec 20 | 17 | -156 | 49 | 0 |
30 Sep 20 | 12 | -96 | 49 | 0 |
30 Jun 20 | 7 | -103 | 49 | 0 |
31 Mar 20 | 6 | -91 | 50 | 0 |
31 Dec 19 | 4 | -86 | 47 | 0 |
30 Sep 19 | 2 | -78 | 41 | 0 |
30 Jun 19 | 2 | -74 | 34 | 0 |
31 Mar 19 | 2 | -63 | 27 | 0 |
31 Dec 18 | 2 | -60 | 24 | 0 |
30 Sep 18 | 2 | -56 | 20 | 0 |
30 Jun 18 | 2 | -56 | 22 | 0 |
31 Mar 18 | 2 | -61 | 27 | 0 |
31 Dec 17 | 2 | -63 | 31 | 0 |
30 Sep 17 | 2 | -63 | 33 | 0 |
30 Jun 17 | 2 | -57 | 29 | 0 |
31 Mar 17 | 2 | -50 | 23 | 0 |
31 Dec 16 | 2 | -45 | 18 | 0 |
30 Sep 16 | 2 | -43 | 16 | 0 |
30 Jun 16 | 2 | -44 | 15 | 0 |
31 Mar 16 | 2 | -43 | 14 | 0 |
31 Dec 15 | 2 | -40 | 13 | 0 |
30 Sep 15 | 2 | -37 | 12 | 0 |
30 Jun 15 | 2 | -33 | 11 | 0 |
31 Mar 15 | 1 | -29 | 10 | 0 |
31 Dec 14 | 1 | -29 | 9 | 0 |
30 Sep 14 | 0 | -24 | 7 | -8 |
30 Jun 14 | 0 | -20 | 5 | -5 |
31 Mar 14 | 0 | -17 | 4 | -2 |
Quality Earnings: OCUL is currently unprofitable.
Growing Profit Margin: OCUL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCUL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: OCUL has a negative Return on Equity (-36.63%), as it is currently unprofitable.